Together Against RA

Two Teams, One Vision, Multiple Drug Candidate Therapies

We’re committed to beating inflammatory disease, and our complementary strengths make us far more capable of doing so.

Knowing our work is tied to the wellbeing of people around the world gives us the determination we need to succeed.

scroll

Gilead, Galapagos, and Inflammation

1987

Gilead Sciences founded

1999

Galapagos founded

2010

Gilead research efforts expand evaluating spleen tyrosine kinase (SYK) inhibition and exploring treatments for inflammatory diseases

2014

Gilead and ONO partner to evaluate Bruton’s tyrosine kinase (BTK) inhibitors for B-cell malignancies and inflammatory diseases1

2014

Galapagos takes decision to focus on the development and execution of molecules in inflammation

2015

Gilead and Galapagos announce global collaboration to address inflammatory diseases2

2018

Gilead and Verily Life Sciences, an Alphabet company, announce a collaboration to better understand the immunologic basis of rheumatoid arthritis, inflammatory bowel disease, and lupus-related diseases3

2019

Gilead and Galapagos embark on a 10-year collaboration to discover and develop transformative therapies in inflammatory diseases4

2019

27 drugs approved globally to date for patients across multiple disease areas5

scroll

Between us we have over 50 active trials investigating 11 separate potential therapies across various pre-clinical and clinical stages.

These include one novel molecule currently in review by global regulatory agencies.

And we’re just getting started.